ONCOTHYREON (NASDAQ: ONTY) $106M (MARKETCAP) BACK IN THE GAME AS MERCK KGAA RE-STARTS CLINICAL TRIALS
Oncothyreon (NASDAQ: ONTY) is a Seattle-based biotechnology association specializing in a growth of innovative healing products for a diagnosis of cancer. The company’s altogether idea is to rise as great as commercialize novel fake vaccines as great as targeted tiny molecules which have a intensity to urge a lives as great as outcomes of cancer patients. Earlier this year, it partnered with German-based Merck KGaA (MRCG.DE) to run clinical trials upon an immune-boosting therapy. These consisted of dual lung cancer trials great well known as Start as great as Inspire as great as a breast cancer investigate called Stride. The 3 trials, all of which engage a BLP25 liposomal vaccine (Stimuvax), consisted of a total 2,600 patients. On Mar 23rd, a single of a patients grown an astonishing inflammation of a brain, great well known as encephalitis, forcing all of Merck’s 3 main trials upon humans to go upon reason until researchers could figure out either it was unequivocally protected to continue. Following this news, Oncothyreon shares plummeted 27% which day as great as have not recovered since.
Today, Oncothyreon can inhale a whine of relief. The association has voiced which a German partner has perceived FDA clearway to re-start 2 of 3 clinical trials of their initial cancer vaccine Stimuvax upon lung-cancer patients, reviving hopes for a pass tube drug. The Phase III Stride hearing in breast cancer stays suspended. In reply to this news, a biotech firm’s shares were up 6.9% in Frankfurt prior to Wall Street non-stop today. Currently, a association is trade during .11, up .50 or 13.85%.
Oncothyreon has no marketed products, though it has alternative cancer drug in a tube upon top of a BLP25-based defence booster. Its partner, Merck, is essentially obliged for a growth of this program, whilst Oncothyreon, accounting for a vast apportionment of a worth investors allot to a company, stands to pick up royalties upon product sales if a diagnosis is successful.
“The resumption of a BLP25 liposome vaccine clinical module is really great headlines for a oncology village as great as non-small dungeon lung cancer patients. If a Start as great as Inspire Phase III trials have been successful, BLP25 liposome vaccine could fool around an critical purpose in a diagnosis of these now underserved patients,” pronounced Dr. Frances Shepherd, executive of a Medical Oncology Princess Margaret Hospital in Toronto, Canada, as great as an questioner of a Start trial, in an Oncothyreon statement.
To perspective this essay during World Market Media click upon a couple below: http://www.worldmarketmedia.com/779/section.aspx/1870/post/oncothyreon-nasdaq-onty-106m-marketcap-back-in-the-game-as-merck-kgaa-re-starts-clinical-trials
Disclosure: no positions